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Abstract
Purpose Little is known about the variables that moderate the
response to psychosocial interventions to decrease depressive
symptoms in cancer patients. The purpose of this study was to
determine whether variables associated with depressive symp-
toms in cancer patients in general moderate the response to a
nurse-led psychosocial intervention in patients with head and
neck cancer.
Methods This study is a secondary analysis of a randomized
controlled trial evaluating the effect of the nurse counseling
and after intervention (NUCAI) on depressive symptoms
12 months after cancer treatment in patients with head and
neck cancer. Of 205 patients, 103 received the NUCAI and
102 care as usual. Twenty-one variables were selected for
analysis and a linear regression analyses including interaction
terms was performed for each variable separately. Significant
moderators were post hoc probed.
Results Four moderators were found: marital status, global
quality of life, emotional functioning, and social functioning.
Patients who were married/living together or had low scores
for global quality of life, and emotional or social functioning
at baseline benefited more from the NUCAI than patients who
were single or with high scores for global quality of life and
emotional or social functioning.
Conclusions Marital status, global quality of life, and
emotional and social functioning of head and neck can-
cer patients should be evaluated to determine whether
they might benefit from a psychosocial intervention to
combat depressive symptoms. Further research is neces-
sary to replicate results and to contribute to the knowl-
edge needed to make screening and personalized patient
care possible.
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Introduction
Head and neck cancer is the sixth most common cancer world-
wide [1] with approximately 690,000 new cases annually
worldwide, which accounts for 4.9 % of the total cancer inci-
dence [2]. Patients diagnosed with head and neck cancer face
unique challenges, because the effects of the cancer and its
treatment are in many cases visible and have a strong negative
impact on diverse functions. Impaired speech, drooling, diffi-
culty chewing, and altered facial appearance are just a few
examples, and these changes can influence social interactions
and alter patients’ self-esteem [3]. In addition, of the patients
recently diagnosed with head and neck cancer 28–29 % is
experiencing depressive symptoms [4], which is 28–39 % af-
ter 6 months [4, 5] and 20 % at 1 year after treatment [6].
Several interventions have proven effective in decreasing de-
pressive symptoms in these patients [7–11].We recently found
that the nurse counseling and after intervention (NUCAI), a
psychosocial intervention, effectively decreased depressive
symptoms 1 year after treatment of head and neck cancer
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[11]. Although this intervention is currently offered to all pa-
tients, it might not be effective in some patients. In order to
gain more insight into which patients might benefit from the
intervention, knowledge is needed of the variables that mod-
erate the effect of the intervention [12].
A recent systematic review [13] identified 14 significant
variables that moderate the outcomes of interventions in pa-
tients with cancer. For example, patients with a poor global
quality of life (QoL), poor interpersonal relationships, and
high emotional expressiveness appeared to benefit more than
other patients. However, the review included a rather broad
range of interventions, such as psychosocial, psycho-educa-
tional, and mind-body interventions aiming to increase psy-
chosocial well-being. Less is known about which variables
moderate depressive symptoms in patients with head and neck
cancer. In a literature search, we found younger age [14, 15],
female gender [16], lower educational level [17, 18], living
alone and unemployment [19], higher tumor stage [14, 20],
adjuvant chemotherapy [16], smoking and daily drinking [17],
avoidance and helpless coping [4, 21, 22], lower social sup-
port [23, 24], lower global QoL [15, 19, 25, 26], lower phys-
ical functioning [27], lower emotional functioning [28], lower
social functioning [27], higher level of pain [29, 30], more
intrusive thoughts [31], lower self-esteem [32], and lower
self-efficacy [32, 33] to influence depressive symptoms in
patients with cancer. The purpose of the current study was to
investigate whether these variables, which are associated with
depressive symptoms in cancer patients, moderate the re-
sponse to a nurse-led psychosocial intervention [11] for the
treatment of depressive symptoms in head and neck cancer
patients.
Materials and methods
This study is a secondary analysis of a randomized controlled
trial (RCT) evaluating the effect of the NUCAI, a psychoso-
cial intervention, in patients with head and neck cancer (reg-
istration number ISRCTN06768231). Newly diagnosed pa-
tients were randomly allocated to an intervention or control
group. Patients in the control group received care as usual,
which consists of a 10-min medical checkup by a specialist
in head and neck cancer in the outpatient clinic every 2months
during the first year after cancer treatment. In addition to care
as usual, patients in the intervention group received the
NUCAI, which consists of six counseling sessions of 60 min
during the first year after cancer treatment, given by a trained
nurse. The 2-monthly sessions were combined with the med-
ical checkup. Participants completed seven questionnaires at
home, before the start of cancer treatment which is considered
as baseline measurement, and at 3, 6, 9, 12, 18, and 24months
after cancer treatment. The primary endpoint was depressive
symptoms 12 months after completion of cancer treatment;
the other measurements were taken to gain insight into the
pattern of change in depressive and health-related QoL
variables.
Results showed that the NUCAI decreased depressive
symptoms and improved physical functioning, emotional
functioning, and pain 12 months after the completion of can-
cer treatment [11]. More details and other, long-term findings
are previously published elsewhere [11, 34].
Patients
Participants were recruited between January 2005 and
September 2007 from the outpatient oral maxillofacial and
the otorhinolaryngology clinics of a Dutch university hospital
before the start of cancer treatment. Eligibility criteria were a
primary diagnosis of squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx, or larynx; treatment with
curative intent; ability to complete questionnaires; and ability
to participate in the intervention. Patients were excluded if
they had a previous or concomitant malignancy and/or were
being treated for depression at time of enrollment or before.
Depression was diagnosed according to Diagnostic and
Statistical Manual of Mental Disorders [35], as stated in the
patients’ medical record. Note that patients without ongoing
treatment for depression were eligible for the trial. After com-
pletion of cancer treatment, participants were randomized to
the intervention or control group, stratified by gender and
tumor stage. Of the 328 eligible patients 63% (n=205) agreed
to participate, 103 participants in the intervention group and
102 participants in the control group. At 12 months, 28 par-
ticipants were lost to follow-up in the intervention group and
27 participants in the control group. Mean reasons were death
(n=16 in intervention group, n=17 in control group) and be-
ing terminally ill (n=4 in intervention group, n=2 in control
group). A total of 146 participants had complete data for anal-
yses. The study was approved by the Medical Ethics
Committee of the University Medical Centre Utrecht.
Eligible patients received verbal and written information
about the study, and all participants provided written informed
consent.
Measures
Sociodemographic, disease-related, and treatment-related
variables Information on age (continuous), gender (male, fe-
male), education level (low (i.e., elementary and lower voca-
tional education), middle (i.e., secondary and secondary vo-
cational education), high (i.e., higher vocational and universi-
ty education), marital status (married/living together, single),
employment status (employed, not employed, retired),
smoking (yes, no), and daily drinking (<3 units alcohol a
day, >3 units alcohol a day) was collected by means of
self-report questionnaires. Information about type of cancer
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(oral cavity/oropharynx, hypopharynx/larynx), tumor stage
(I–II, III–IV), and treatment (surgery, radiotherapy, chemora-
diation, combination) was obtained from medical records.
Depressive symptoms Depressive symptoms were measured
with the CES-D [36]. This 20-item self-report questionnaire
gives a total score ranging from 0 to 60. A high score reflects a
high level of depression. The CES-D has shown good psycho-
metric properties in Dutch patients with head and neck cancer
[4].
Health-related quality of life (HRQoL) Global QoL, physical
functioning, role functioning, emotional functioning, cogni-
tive functioning, and social functioning were assessed with
the EORTCQLQ-C30 version 3.0 [37] and pain with the head
and neckmodule QLQH&N35 [38]. A range of 0–100 is used
and a high score reflects a high level of functioning or a high
level of pain. Both are widely used and have good psychomet-
ric properties in patients with head and neck cancer [38, 39].
Coping strategy Coping was assessed with the shortened
Dutch version of the Coping Inventory for Stressful
Situations (CISS) [40]. This 21-item self-report questionnaire
measures three dimensions of coping: task-oriented, emotion-
oriented, and avoidance-oriented coping. Item scores range
from 1 (not at all) to 5 (very often). A higher score on each
dimension reflects a higher probability of using that coping
strategy. The CISS demonstrated good psychometric proper-
ties in Dutch patient with internal diseases [41].Chronbach’s
alpha in the present sample was 0.83 for the task-oriented
scale, 0.83 for the emotion-oriented scale, and 0.71 for the
avoidance-oriented scale.
Social support Social support was measured with the short
version of the Social Support List - Interactions (SSL 12-I)
[42]. This questionnaire assesses the extent of perceived re-
ceived social support by means of social interactions with
members of the primary social network. It consists of 12 items
with possible item scores ranging from 1 (seldom or never) to
4 (very often) with a higher score reflecting more social sup-
port. The SSL 12-I has shown good psychometric properties
in Dutch elderly [42] and Dutch patients with rheumatoid
arthritis [43]. Chronbach’s alpha in the present sample was
0.91.
Potential moderators
The following variables were entered in the analyses: age,
gender, educational level, marital status, employment status,
tumor stage, type of treatment, smoking, daily drinking, task
coping, emotion coping, avoidance coping; social support,
global QoL, physical functioning, emotional functioning, so-
cial functioning, and pain. These variables have been reported
in the literature to be associated with depressive symptoms.
We additionally included the variables assessed in the NUCAI
study, namely, head and neck cancer specific tumor site, role
functioning and cognitive functioning, even though there is no
evidence in the literature that these variables have a moderat-
ing effect. The variables intrusive thoughts, self-esteem, and
self-efficacy, which showed to be associated with depressive
symptoms, could not be included in the moderator analyses
because we did not collect these variables in the NUCAI
study. Overall, 21 variables were selected for analysis.
Statistics
To determine whether there were differences in potential mod-
erators between the intervention and control groups, we per-
formed t-tests for continuous variables and X2 tests for cate-
gorical variables. The variance of the residuals was tested by a
scatterplot to examine homoscedasticity and linearity. A linear
regression analysis was performed for each moderator sepa-
rately to identify whether the selected variable moderated the
effect of the intervention on depressive symptoms at
12 months after cancer treatment. Continuous potential mod-
erators were centered to reduce multicollinearity, and for the
categorical potential moderators, educational level, employ-
ment status, and type of treatment, dummies were created.
The first category was used as reference. The linear regression
model contained the continuous depressive symptom score at
12 months as dependent variable. Group (intervention versus
control), the centered potential moderator at baseline, the
group by moderator interaction, and the centered continuous
baseline depressive symptoms score were entered as indepen-
dent variables. All participants who completed the baseline
and the 12-month assessments were included in the full-case
analyses.
In addition to the full-case, an intention to treat analyses
was performed. Participants who did not complete the 12-
month assessment but who minimally completed the baseline
and 3-month assessments were included. To determine wheth-
er there were differences in potential moderators between the
participants in the full-case analyses and the additional partic-
ipants who entered the intention-to-treat analyses, t-tests were
performed for continuous variables and X2 tests for categorical
variables. Missing values were imputed in the intention-to-
treat sample. Multiple imputation (10×) was carried out for
missing 12 months post-cancer treatment score for depressive
symptoms as well as missing baseline scores of, coping strat-
egy, social support, cognitive functioning, and depressive
symptoms. Constraints were given for each variable. All other
variables were used as indicator.
The linear regression analyses were repeated and the
pooled outcome of the 10 imputation datasets was used as
result.
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Table 1 Participant characteristics at baseline










Years (mean (SD)) 59.5 (8) 59.9 (9) 60.1 (10) 60.7 (10)
Gender (no. (%))
Male 53 (73) 55 (75) 62 (70) 64 (70)
Female 20 (27) 18 (25) 26 (30) 27 (30)
Educational level (no. (%))
Low 32 (44) 33 (45) 37 (42) 37 (41)
Middle 26 (36) 29 (40) 32 (36) 41 (45)
High 15 (21) 11 (15) 19 (22) 13 (14)
Marital status (no. (%))
Married/living together 54 (74) 53 (73) 63 (71.6) 67 (74)
Single 19 (26) 20 (27) 25 (28.4) 24 (26)
Employment status (no. (%))
Employed 25 (34) 30 (41) 31 (35) 34 (37)
Not employed 23 (32) 25 (34) 29 (33) 34 (37)
Retired 16 (22) 17 (23) 19 (22) 21 (23)
Unknown 9 (12) 1 (1) 9 (10) 2 (2)
Tumor site (no. (%))
Oral cavity and oropharynx 46 (63) 48 (66) 57 (65) 61 (67)
Hypopharynx and larynx 27 (37) 25 (34) 31 (35) 29 (32)
Unknown primary – – – 1 (1)
Tumor stageb (no. (%))
I–II 43 (59) 47 (64) 51 (58) 55 (60)
III–IV 30 (41) 26 (36) 37 (42) 36 (40)
Type of treatment (no. (%))
Surgery 17 (23) 26 (36) 22 (25) 29 (32)
Radiotherapy 21 (29) 21 (29) 25 (28) 24 (26)
Chemoradiation 11 (15) 8 (11) 12 (14) 12 (13)
Combination 24 (33) 18 (25) 29 (33) 26 (29)
Smoking (no. (%))
Yes 29 (40) 33 (45) 33 (38) 37 (41)
No 44 (60) 40 (55) 55 (63) 54 (59)
Daily drinking (no. (%))
Yes 26 (36) 22 (30) 27 (31) 27 (30)
No 47 (64) 51 (70) 61 (69) 64 (70)
Coping strategy (mean (SD))c, d
Task oriented 18 (6) 18 (5) 18 (6) 17 (5)
Emotion oriented 12 (5) 13 (5) 12 (5) 13 (5)
Avoidance 12 (5) 12 (3) 12 (5) 12 (3)
Social support (mean (SD))c, d 2.9 (0.6) 2.6 (0.5) 2.9 (0.6) 2.7 (0.5)
Global quality of life (mean (SD)) 68 (23) 68 (22) 67 (23) 66 (23)
Physical functioning (mean (SD)) 84 (19) 88 (16) 84 (16) 87 (18)
Role functioning (mean (SD)) 76 (28) 78 (29) 76 (28) 78 (29)
Emotional functioning (mean (SD)) 64 (25) 67 (25) 65 (25) 67 (23)
Cognitive functioning (mean (SD))d 82 (22) 85 (21) 84 (22) 84 (22)
Social functioning (mean (SD)) 82 (23) 84 (21) 83 (22) 83 (21)
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Effect sizes (ES) were calculated for each regression model
in order to estimate the variance explained by the interaction
term. Therefore, the proportion of variance accounted for in
the model with the interaction term was subtracted from the
model without the interaction term. Cohen’s [44] cutoff points
were used to indicate a small (ES=0.02), medium (ES=0.15),
or large (ES=0.35) effect. In addition, the achieved power for
each regression model was calculated using the statistical soft-
ware of G*Power [45].
Finally, the significant moderators were post hoc probed to
determine if the relation between depressive symptom and
group (intervention vs control) is significant for the categories
of the moderators. For the continuous moderators the catego-
ries −1 SD, mean, and +1 SD score were generated. For cat-
egorical moderators, the existing categories were used. The
statistical software PROCESS of A. Hayes [46] was used for
the post hoc probing analyses.
All analyses were, unless otherwise stated, performed




In total, 103 participants were randomized to the intervention
group and 102 to the control group. A minimum of two as-
sessments were available for 88 participants in the interven-
tion group and 91 participants in the control group (intention-
to-treat analyses), and 73 participants in the intervention group
and 73 participants in the control group completed the 12-
month post-cancer treatment assessment (full-case analyses)
(Table 1). The intervention and control groups were similar in
terms of sociodemographic, disease-related, and treatment-
related characteristics and potential moderators. In addition,
there were no significant differences between the full-case
participants (n=146) and the additional participants who en-
tered the intention-to-treat analyses (n=33) (all p>0.05).
Moderator analyses
The data was considered to be normally distributed, homosce-
dastic, and linear for all potential moderators. In the full-case
analyses, the linear regression analyses identified four signif-
icant moderators: marital status (b=−6.75, p=0.04), global
QoL (b=−0.14, p=0.03), emotional functioning (b=−0.14,
p=0.02), and social functioning (b=−0.13, p=0.04)
(Table 2). In the intention-to-treat analyses, emotional func-
tioning (b=−0.14, p=0.02) and social functioning (b=−0.15,
p=0.03) were identified as moderators. A trend to significance
was found for marital status (b=−5.96, p=0.08) and global
QoL (b=−0.14, p=0.05) (Table 2).
Effect sizes ranged from 0.00 to 0.25 and achieved power
from 0.05 to 0.56 for gender in the full-case analyses and
emotional functioning in the intention-to-treat analyses, re-
spectively (Table 2). Post hoc probing analyses revealed a
significant group difference in marital status in favor of pa-
tients who were married or living together (b=−4.25, p=0.01)
compared to patients who were single. Furthermore, patients
with low (−1 SD) baseline scores on global QoL (b=−5.65,
p=0.01), emotional functioning (b=−5.99, p=0.00), and so-
cial functioning (b=−5.41, p=0.01) differed significantly
from patients with mean or high (+1 SD) baseline scores
(Table 3). This indicates that patients who were married or
living together, and patients with low baseline scores on glob-
al QoL, emotional functioning, and social functioning
responded better to the NUCAI than patients who were single
or had mean or high baseline scores. Regression lines for each
relationship between group (control vs NUCAI) and depres-
sive symptom score at 12 months post-cancer treatment as
moderated by marital status, global QoL, emotional function-
ing, or social functioning are given in Fig. 1.
Table 1 (continued)









Pain (mean (SD)) 35 (26) 32 (25) 36 (26) 31 (24)
Depressive symptoms (mean (SD))d 12 (9) 13 (11) 13 (9) 13 (10)
SD standard deviation
a Data is given of participants who completed a minimum of two measurements (n=179)
b Tumor stage according to the TNM Classification of Malignant Tumors
c Incomplete baseline data for participants in full-case analyses: task-oriented coping (n=129), emotion-oriented coping (n=131), avoidance coping (n=
132), and social support (n=137)
d Incomplete baseline data for participants in intention-to-treat analyses: task-oriented coping (n=154), emotion-oriented coping (n=157), avoidance
coping (n=159), social support (n=165), cognitive functioning (n=178) and depressive symptoms (n=178)
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Age, gender, educational level, employment status, tumor
stage, type of treatment, smoking, daily drinking, task coping,
emotion coping, avoidance coping, social support, physical
functioning, pain, tumor site, role functioning, and cognitive
functioning did not moderate the effect of the NUCAI on
depressive symptoms 12 months posttreatment.
Discussion
The present study investigated moderators of the response to a
nurse-led psychosocial intervention, the nurse counseling and
after intervention (NUCAI). The NUCAI has been found to
decrease depressive symptoms 1 year after treatment of head
Table 2 Potential moderators of the intervention effect in full-case analyses and intention-to-treat analyses
BL—12 M BL—12 M
Full case analyses (n=146) Intention-to-treat analyses (n=179)
Potential moderators p 95 % CI Unstand. β ESc Power p 95 % CI Unstand. β ESc Power
Sociodemographic, disease-related, and treatment-related variables
Age 0.28 −0.51 to 0.15 −0.18 0.005 0.14 0.55 −0.48 to 0.26 −0.11 0.005 0.16
Gender 0.79 −5.51 to 7.23 0.68 0.000 0.05 0.69 −4.94 to 7.50 1.28 0.001 0.07
Education 0.004 0.12 0.002 0.09
Low vs middle 0.54 −8.19 to 4.33 −1.93 0.94 −6.87 to 6.38 −0.24
Low vs high 0.38 −11.65 to 4–49 −3.58 0.83 −9.85 to 7.91 −0.97
Marital status 0.04* −13.02 to −0.48 −6.75 0.019 0.38 0.08 −12.59 to 0.67 −5.96 0.018 0.43
Employment status 0.016 0.31 0.013 0.31
Employed vs not employeda 0.11 −1.22 to 12.11 5.45 0.33 −3.70 to 10.86 −3.58
Employed vs retireda 0.12 −1.57 to 13.25 5.84 0.21 −3.06 to 13.59 5.27
Tumor site 0.27 −2.58 to 9.14 3.28 0.005 0.14 0.61 −4.55 to 7.69 1.57 0.002 0.09
TNM status 0.68 −4.65 to 7.07 1.21 0.001 0.07 0.81 −5.37 to 6.88 0.75 0.001 0.07
Treatment 0.006 0.15 0.002 0.09
Surgery vs radiotherapy 0.26 −3.14 to 11.73 4.30 .83 −6.92 to 8.68 0.88
Surgery vs chemoradiation 0.52 −6.42 to 12.55 3.06 0.96 −9.95 to 10.43 0.24
Surgery vs combination 0.51 −5.07 to 10.22 2.58 1.00 −7.65 to 7.66 0.01
Smoking 0.07 −0.34 to 11.06 5.36 0.014 0.29 0.24 −2.42 to 9.59 3.59 0.007 0.20
Daily drinking 0.58 −7.75 to 4.36 −1.69 0.001 0.07 0.46 −8.84 to 3.97 −2.44 0.003 0.11
Coping strategy
Task copingb 0.97 −0.52 to 0.55 0.01 0.000 0.05 0.92 −0.55 to 0.49 −0.03 0.001 0.07
Emotion copingb 0.20 −0.21 to 0.97 0.38 0.008 0.17 0.28 −0.30 to 1.01 0.36 0.007 0.20
Avoidance copingb 0.60 −0.57 to 0.99 0.21 0.001 0.07 0.76 −0.67 to 0.93 0.13 0.002 0.09
Social supportb 0.06 −10.94 to 0.24 −5.35 0.016 0.31 0.54 −7.95 to 4.17 −1.89 0.004 0.13
EORTC-QLQ-C30 and H&N35 variables
Global quality of life 0.03* −0.26 to −0.02 −0.14 0.021 0.41 0.05 −0.28 to 0.00 −0.14 0.024 0.54
Physical functioning 0.55 −0.21 to 0.11 −0.05 0.001 0.07 0.50 −0.23 to 0.11 −0.06 0.003 0.11
Role functioning 0.24 −0.16 to 0.04 −0.06 0.005 0.14 0.26 −0.16 to 0.05 −0.06 0.007 0.20
Emotional functioning 0.02* −0.25 to −0.02 −0.14 0.024 0.46 0.02* −0.26 to −0.02 −0.14 0.025 0.56
Cognitive functioning 0.18 −0.22 to 0.04 −0.09 0.007 0.17 0.32 −0.20 to 0.07 −0.07 0.004 0.13
Social functioning 0.04* −0.26 to −0.01 −0.13 0.018 0.36 0.03* −0.27 to −0.02 −0.15 0.022 0.51
Pain 0.31 −0.06 to 0.17 0.06 0.004 0.12 0.18 −0.04 to −0.20 0.08 0.010 0.27
BL baseline measurement, CI confidence interval, Unstand. β undstandardized beta, ES effect size
*p value is <0.05
a Patients whose employment status was unknown were not included in analyses
b Incomplete data in full-case analyses: task-oriented coping (n=129), emotion-oriented coping (n=131), avoidance coping (n=132), and social support
(n=137)
c Cohen’s (1988) cutoff points were used to indicate a small (ES=0.02), medium (ES=0.15), or large (ES=0.035) effect
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and neck cancer [11]. In this secondary analysis, we found that
patients who were married/living together had low baseline
scores on global QoL, emotional functioning, or social func-
tioning benefitted more of the NUCAI, resulting in lower
Table 3 Post hoc probing of the significant moderators
Moderator baseline value p value 95 % CI β value
Marital status Married/living together – 0.01* −7.49 to −1.01 −4.25
Single – 0.36 −2.86 to 7.86 2.50
Global quality of life −1 SD 45.52 0.01* −9.61 to −1.70 −5.65
Mean 68.26 0.08 −5.25 to 0.31 −2.47
+1 SD 91.01 0.72 −3.23 to 4.65 0.71
Emotional functioning −1 SD 40.30 0.00* −9.96 to −2.01 −5.99
Mean 65.26 0.07 −5.38 to 0.20 −2.59
+1 SD 90.22 0.69 −3.12 to 4.73 0.80
Social functioning −1 SD 60.70 0.01* −9.39 to −1.44 −5.41
Mean 83.11 0.08 −5.26 to 0.32 −2.47
+1 SD 100 0.89 −3.75 to 3.25 −0.25
Analyses were performed in the full-case group (n=146)
CI confidence interval, β beta, SD standard deviation
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Fig. 1 Regression lines for the relationship between group (intervention vs control) and depressive symptom score at 12 months post-cancer treatment,
as moderated by marital status (a), global quality of life (b), emotional functioning (c), or social functioning (d)
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depressive symptom scores 12 months posttreatment, than
patients who were single or had mean or high baseline scores
on global QoL, emotional functioning or social functioning.
Patients with low baseline scores for emotional functioning
showed a statistical significant improvement of almost 6
points on the depressive symptoms scale. Although a minimal
clinically important difference of the CES-D is not yet
established, we considered this difference as clinical signifi-
cant, according to Norman et al. who showed that a change of
half a standard deviation indicates a clinical relevant differ-
ence [47]. Only one study was found in the literature that
explored the moderating effect of emotions in patients with
cancer. Manne et al. [28] showed, in a large RCT involving
women with gynecological cancer, that women who were
more expressive of positive emotions benefitted more from a
supportive counseling intervention thanwomenwhowere less
expressive of positive emotions. Results for negative emotions
were not computed because of the low internal consistency of
the data. Our results are inconsistent with those ofManne et al.
[28], which could be due to the different types of cancer stud-
ied and the gender of the participants (solely women versus
70 % men in our study). In addition, Gamper et al. [49] re-
cently defined emotional functioning as a variable that covers
aspects of anxiety, depression, and general distress, which is
much broader than expression of emotions alone.
We also found that patients with head and neck cancer who
had low scores for social functioning at baseline responded
statistically and clinically significantly better, with a decrease
of 5.4 points on the depressive symptoms scale, to the NUCAI
than patients with high scores for social functioning.
Balderson et al. [27] reported that social/family well-being
was related to lower psychological distress in patients with
prostate cancer, which is in line with our results.
The full-case analyses showed that patients who were
married/living together had fewer depressive symptoms (a
decrease of 4.3 points) 1 year after cancer treatment than pa-
tients who were single and thus benefited more from the
NUCAI. The intention-to-treat analyses showed the same
trend. It should be mentioned that, with the NUCAI, patients
are encouraged to bring their partners to intervention sessions.
Mikoshiba et al. [19] found that living alone was associated
with an increased likelihood of depressive symptoms in pa-
tients with liver cancer. Perhaps if a partner follows the inter-
vention with the patient, he/she can discuss the intervention
with the patient at home and might stimulate and support the
patient.
A poorer global QoL at baseline was also found to be a
moderator of the effect of the NUCAI in both the full-case and
intention-to-treat analyses, with patients with a worse global
QoL at baseline responding better (a decrease of 6.7 points on
the depressive symptoms scale) to treatment than patients with
a better global QoL. While we did not find any articles in the
literature that expressly investigated this, several studies have
shown that higher depressive symptom scores or depression
are related to a lower global QoL in cancer patients [19, 25,
26]. Overall, no significant improvements were found for pa-
tients who had high (+1 SD) global QoL, emotional function-
ing, and social functioning scores. The CES-D is found to be
sensitive to changes in depressive symptoms after intervention
[48]; however, it could be that these patients with high scores
had little room to improve and therefore only minor changes
in depressive symptoms could be established. This should be
considered when offering the NUCAI to patients.
Other studies have shown that social demographic vari-
ables (age, gender, educational level, working status),
disease-related variables (tumor stage, type of treatment), or
health behavior-related variables (smoking, drinking) are re-
lated to increased levels of depressive symptoms [13, 14,
16–19]. We did not find these variables to moderate the re-
sponse to the NUCAI. The NUCAI is patient driven, and it is
possible that the nurses personalized the intervention on the
basis of these variables, thereby providing a tailored interven-
tion. Overall, there is no evidence at this point that clinical
variables should be used when selecting patients with head
and neck cancer for a psychosocial intervention.
Hence, the NUCAI seems to be of most benefit for
head and neck cancer patients who have poor scores
on emotional functioning, social functioning, and global
QoL. In addition, patients who are single should be
given extra attention and should be encouraged to bring
a relative or friend to the intervention sessions.
Interestingly, the European Organisation for Research and
Treatment of Cancer (EORTC) is developing a computerized
adaptive testing measure based on an item bank for, among
others, emotional functioning, to be used as a screening tool in
cancer patients [49]. This extensive project is in its last phase
and seems to be promising for future screening possibilities
and could be extended with the other moderators found in this
study.
Our findings represent a first step to distinguishing between
patients with head and neck cancer who might or might not
benefit from a psychosocial intervention. However, the results
are secondary analyses and the following limitations should
be considered when interpreting outcome. First, this study was
not powered for moderator analyses but for the efficacy of the
intervention. The effect sizes of the significant moderators
varied between 0.018 and 0.024 which is considered to be a
small effect [44]. In addition, the power varied between 0.36
and 0.46 which implicate that a larger sample size is needed to
detect a relationship between the moderator and the interven-
tion effect without committing a type II error. In addition,
because of the explorative nature of the study, the p values
were not adjusted for multiple testing. Lastly, not all the var-
iables that are associated with depressive symptoms could be
incorporated in the analyses because they were not measured
in the NUCAI study.
2424 Support Care Cancer (2015) 23:2417–2426
In conclusion, little is known about the variables that mod-
erate the response to a psychosocial intervention in head and
neck cancer patients. Analyses showed that patients who had
poor scores for emotional functioning, social functioning, and
global QoL at baseline and who were married or living togeth-
er benefitted more from the NUCAI than patients with high
scores and who were single. We suggest that the screening of
patients with head and neck cancer for eligibility for a psycho-
social intervention should be based on patients’ global QoL,
emotional functioning, and social functioning, with extra at-
tention being paid to patients who are single. Because of the
explorative nature of this study further, well powered, research
is necessary to replicate our results and to provide personal-
ized patient care, so that available resources (time, staff, and
money) can be used in the best possible way.
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